Non classé

Key Takeaways from ESMO GI 2025 on Pancreatic Cancer

Promising new therapies are emerging. Daraxonrasib, a KRAS-targeting pill, is in Phase 3 trials after earlier encouraging results and FDA Breakthro...

Read

DiCE Grants — Autumn 2025

DiCE opens Autumn 2025 grants: unrestricted operational support for Full and Associate Members, plus the €5,000 Wolfram Nolte Memorial Award for ...

Read

VOICE: A Life-Changing Training in Cancer Research

Patient advocates joined VOICE in London for a week of immersive learning at Barts Cancer Institute. Exploring cancer biology, research methods, an...

Read

Promising Advances in Pancreatic Cancer: ASCO 2025 Highlights

Phase III PANOVA-3 trials show that Tumour-Treating Fields Improve Overall Survival Final data from the Phase 3 PANOVA-3 study of tumour treating f...

Read

Amplifying the Patient Voice: Reflections from the WECAN Academy 2025

DiCE Patient Ambassador Mila Ogalla Toledo shares her experience at the WECAN Academy 2025 in Rome—a three-day training for cancer advocates acro...

Read

AIDA Project Uses Artificial Intelligence to Improve Treatment for a Common Cause of Gastric Cancer

The AIDA project has developed an AI system that helps doctors choose more effective treatments for H. pylori, a major cause of gastric cancer. Bas...

Read

A New Chapter for DiCE: Board Chair Shares Vision and Thanks

We welcome our new Board of Directors forming the core leadership of Digestive Cancers Europe. Their leadership will strengthen our mission. We tha...

Read

READI for Inclusion: Making Clinical Trials Fairer for All

The READI Project is paving the way for more inclusive clinical research. Supported by IHI, this 73-partner consortium is tackling exclusion by emp...

Read

Immunotherapy Added to Chemotherapy Shows Breakthrough Results in Early-Stage Gastric Cancer

Global study brings hope to people diagnosed with early-stage gastric cancer, showing that a combination of immunotherapy and chemotherapy may sign...

Read

ASCO 2025: New Insights and Hope for Colorectal Cancer Patients

Exercise, targeted therapy, immunotherapy, and aspirin: ASCO 2025 showcased breakthroughs in colorectal cancer care that support longer survival an...

Read

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.